Alpha Cognition Inc. (ACOG) Earnings Call Transcript
November 13, 2025
Earnings Call Speaker Segments
Thanks, Vaughn. Hello, everyone, and I appreciate you being with us this afternoon for Alpha Cognition's conference call on our financial results for the third quarter. A press release went out from the company after the market closed today to share those results; joining me on this call are Michael McFadden, Alpha Cognition's Chief Executive Officer, and Lauren D'Angelo, our Chief Operating Officer. You can access today's call through the investor section of the company's website, www.alphacognition.com. At points during this call, management might deliver certain forward-looking statements about future events and how the company will perform going forward. Such forward-looking statements reflect Alpha Cognition's present view of existing trends and information. No forward-looking statement of this kind is a guarantee of future performance, and each involves risks and uncertainties, including the ones described in the risk factors section of the company's latest SEC filings. Actual results could differ materially from what these forward-looking statements project. For those of you who might be listening to the replay, this call is taking place and being recorded on November 13, 2025. The company may have issued additional announcements about the topics discussed since then. Please consult the company's most recent press releases and current filings with the SEC. Alpha Cognition disclaims any obligation to update these forward-looking statements except as applicable securities laws require. I'll now hand the call over to Michael.
Thanks, Henry. Good afternoon, everybody, and I appreciate you spending time with us on today's call. This is our second quarter of earnings since ZUNVEYL's commercial launch for mild to moderate Alzheimer's disease treatment. During 2025's third quarter, we saw sales growth for ZUNVEYL, ongoing involvement in the market's long-term care segment, further pricing moves on ZUNVEYL, advancement with our business development partner CMS Pharma, plus additional publications highlighting ZUNVEYL data and the opportunity in the Alzheimer's market. After the quarter closed, the company brought in more capital, reinforcing its balance sheet and enabling investment in a major growth opportunity that has arisen around symptom management for Alzheimer's disease. That capital will go toward speeding up growth and funding sales, marketing, and research for ZUNVEYL in addressing behavioral symptoms that frequently accompany Alzheimer's. Throughout the quarter, the company achieved meaningful strides on our commercial launch. Our sales and marketing team has reached out to more than 1,850 prescribers within the long-term care market, and we observed prescriptions being written across over 500 nursing homes. Since launch, duplicative prescriptions have been written in 70% of those nursing homes, a robust sign of product trial. We anticipate new and duplicative home figures will climb considerably over upcoming quarters. On clinical performance, ZUNVEYL seems to be doing well, with anecdotal reports of improved cognition, reduced or ameliorated behaviors, and still-limited reports of adverse events. GI adverse events being reported remain in the low single digits, which points to a medication that is well tolerated. One focus for the company in 2025 has been sharing medical information that offers rationale for ZUNVEYL in treating Alzheimer's; this quarter, the medical team had seven abstracts accepted for publication, with three poster presentations delivered to long-term care pharmacy at ASCP. That stands for the Association of Consultant Pharmacists, in October. Two poster presentations were given to psychiatrists and neuroscientists at the Neuroscience Education Institute last week, and two poster presentations are set for Alzheimer's researchers at clinical trials for Alzheimer's disease, or CTAD, in December. Our medical team keeps publishing compelling data in the Alzheimer's segment concerning cognition and behavioral symptoms. On research and development, the company will begin two studies in the long-term care setting, one in Q4 of 2025 and one in Q1 of 2026. These two studies, which we call CONVERGE and BEACON, will evaluate ZUNVEYL's cognitive benefits, tolerability, effects on sleep and behaviors, and utilization parameters such as polypharmacy. These studies will yield critical data for ZUNVEYL and the patient population that is our commercialization focus. We expect CONVERGE to finish in Q3 of 2026, and BEACON to finish in Q4 2026. Both studies are lower-cost, and they are accounted for in our current spend guidance for this year and in 2026. The company will also begin a prospective registry trial in Q1 of 2026 called RESOLVE. This is going to give us useful insight into how well ZUNVEYL works against the behavioral symptoms that come along with Alzheimer's disease. The study is also going to look at how well patients tolerate ZUNVEYL, plus the strain on caregivers. Those are key things every provider weighs when they pick a therapy, and we believe this information will be critical for how ZUNVEYL is positioned with physicians and payers. We'll share more details about the registry trial during Q1. Turning to business development, our partner CMS Pharma submitted a filing in China seeking approval, and that filing has been accepted for review. We expect the 18-month review timeline to be the one that applies to our application, with approval possibly coming at the end of 2026. We're also continuing to move our sublingual formulation forward, and we expect the formulation and tasting work to wrap up in Q1 of 2026. The company intends to conduct a comparative PK study against existing formulations, and that data will serve as the foundation for an IND submission in Q3 of 2026. The company keeps managing our expenses carefully as we get ready to take advantage of new opportunities emerging in the long-term care market. The most important one is making sure ZUNVEYL is positioned as well as possible, since it delivers clinically meaningful benefits on both the cognitive and behavioral symptoms tied to Alzheimer's. Lauren will walk through our commercialization process in a moment, but first, Henry, will talk about the company's financials. Henry?
Thanks, Michael. Hello, everybody, and I appreciate you being with us this afternoon. While I go over what we achieved in the third quarter of 2025, please have a look at the press release issued today along with our Form 10-Q. We'll begin with the figures; during the quarter, our total revenue came to $2.8 million, which was powered by $2.3 million of net product sales from ZUNVEYL, our lead commercial product, plus $507,000 of licensing revenue stemming from the collaboration we have with CMS Pharma. What these results demonstrate is encouraging early traction, and they establish a strong base for scalable growth across the coming quarters. Operating expenses overall amounted to $8.2 million, which included $633,000 of cost of goods sold and cost of revenues, together with $7.5 million in operating expenses, versus $2.5 million of operating expenses during Q3 a year ago. That rise primarily comes from greater SG&A costs as we increased our commercial launch efforts behind ZUNVEYL and grew our operations in support of expansion; this produced an operating loss of $5.3 million, compared with $2.5 million during the same period in 2024. Now to net income performance: we recorded a net loss of $1.3 million, equal to $0.08 basic loss per share and $0.30 diluted loss per share, versus a net loss of $1.9 million, or $0.31 per share on both a basic and diluted basis, a year earlier. This improvement is due to a $3.7 million non-cash gain tied to changes in the fair value of derivative liabilities, as well as $378,000 of interest income during the quarter. Moving next to the balance sheet, where our capitalization remains strong. On September 30, we had $35.4 million of unrestricted cash and cash equivalents, and that figure excludes roughly $38 million in net proceeds we raised during October via our equity offering and overall alignment exercise. Taken together, these resources give us a strong balance sheet along with an operational runway reaching well into 2027, which affords us the flexibility to pursue our commercial and corporate priorities confidently. Finally, a quick note on guidance. Going forward, although no formal revenue guidance is being offered today, we anticipate continued sequential growth in ZUNVEYL sales as awareness and payer access broaden throughout 2026. On the expense side, we now anticipate that operating expenses for full year 2025 will fall within a range of $28 million to $30 million. This represents a decrease relative to prior guidance, which mirrors our sustained emphasis on cost discipline, operational efficiency, and prudent resource allocation. The areas we concentrated on included contract negotiations, reassessing marketing spend, and postponing the hiring of certain positions that we consider more cost-effective to outsource over the near term. All in all, the third quarter was a stretch of continued momentum, distinguished by steady revenue growth from ZUNVEYL and a solid financial position. Our early market progress is encouraging, and as we look toward the rest of the year, our team stays focused on disciplined execution, sustainable growth, and building long-term value for our shareholders. Thank you. I'll now hand the call over to Lauren for a discussion of commercial progress. Lauren?
Thanks, Henry. In the third quarter, the U.S. rollout of ZUNVEYL within long-term care kept showing a lot of strength. Following a solid debut earlier in the year, Q3 numbers pointed to demand and prescriber uptake both speeding up, which highlights how ZUNVEYL is playing a growing role in Alzheimer's disease treatment. We recorded another stretch of robust expansion. Ex-factory purchases rose 44% versus Q2, going from 2,640 bottles up to 3,808 bottles. The company thinks this does mirror larger inventory holdings among several wholesalers and might have some impact on Q4 purchasing. Demand sales, meaning bottles dispensed, increased at a faster rate still, up 102% from the second quarter. Of note, since June we've seen month-over-month gains in the double digits. Growth occurred broadly across every region, reflecting deeper engagement with facilities and greater prescriber confidence. Fulfillment rates stay elevated, and patient titration along with persistence continue to match expectations. Our commercial footprint keeps expanding at a rapid clip. We engaged 2,038 homes during Q3, which brought total reach since launch to 2,942 unique homes. Among those, 605 homes have placed orders for ZUNVEYL, with 70% of those homes reordering and 15% placing new orders in September. Beyond that, Q3 order volume was evenly divided between the 5 mg and 10 mg strengths. That even division demonstrates how well our drug is tolerated, since patients reliably get to the therapeutic dose—something existing treatment options have not been able to deliver. During Q3, our field team met face to face with 1,850 prescribers, which lifted cumulative engagements since launch to 2,630. Orders came from 576 prescribers in Q3, up 55% versus Q2, and 62% of those prescribers placed more than one order—a clear indicator of mounting confidence and clinical fit. Together, these figures reflect deeper engagement and continuing momentum throughout our prescriber base. Market access is still progressing according to plan. Following the National Health Plan deal we struck earlier in the year, our focus shifted to getting coverage up and running and expanding conversations with payers across the regions. Submissions for 2027 Medicare Part D are still proceeding as planned. Under the contract we previously disclosed, 15% of business now covers ZUNVEYL without restrictions. As for this PBM, we don't have any further insight into when other plans might reach a formulary decision on ZUNVEYL. Management anticipates signing a second PBM payer contract before 2025 ends, and expects it will take two quarters before that business delivers unrestricted coverage. We also made a strategic adjustment to WAC, setting it at $820.15 per month, which brings our pricing in line with both ZUNVEYL's differentiated value and CNS benchmarks. According to what payers have told us, the price is still competitive among long-term care formularies. Our field and operations teams are still completely deployed and working very effectively. Our reps bring an average of 16 years of industry experience, with 10 years in long-term care, and they are driving meaningful clinical education and adoption throughout this complex channel. We have kept product availability and fulfillment rates strong. What we learn operationally from payer interactions is making the prior authorization process more efficient, which speeds up time to therapy and improves patient access. Our reimbursement group has expanded, allowing us to assist homes more effectively with prior authorization processing, which brings us into tighter alignment with customers and lets us spot and resolve issues faster. Financial discipline keeps guiding how this organization operates, so that each choice about pricing, promotions, and resources serves the goal of building value over the long term. HCP education and brand reinforcement stay at the center of what our marketing does. Whether through digital channels or face-to-face efforts, we keep highlighting the differentiated clinical profile of ZUNVEYL, especially the label-consistent advantages seen across multiple behavioral domains as measured by the Neuropsychiatric Inventory. Reactions to our updated clinical messaging and the titration support toolkit have been extremely favorable, which strengthens prescriber confidence and supports proper initiation. Heading into Q4 and getting ready for 2026, our priorities stay clear and unchanged: broaden ZUNVEYL's footprint into more long-term care homes, build deeper ties with prescribers who show high potential, improve payer access and speed up approval timelines, and maintain disciplined execution in every function. Accelerating uptake of ZUNVEYL, lasting growth in demand, and widening payer access highlight both our solid commercial base and the outstanding work of our team. We stay confident that we can keep driving growth and expand access for patients and caregivers in the coming quarters. With that, I'll hand things over to Michael.
Thanks; to sum up, our team remains centered on execution: making additional calls to high-value HCP targets, handling the restrictions currently in place with health plans, and pulling through contracts with other parties. Our focus is on growing prescriptions by home and by prescriber so we can seize the opportunity we see for ZUNVEYL in the long-term care segment. Our business development team has collaborated with our partner in Asia to submit ZUNVEYL ahead of schedule and to secure what we expect will be several approvals in 2026, which will bring in additional revenues for the company. The company believes ZUNVEYL offers us a disruptive opportunity. Over the coming quarters, we'll concentrate on selling efforts and continued financial discipline. We'll now take questions. Operator?
Absolutely. We're extremely focused on every one of the plans that counts over the long haul in long-term care. On earlier calls, I believe I've mentioned that there are 4 major Medicare plans, PBMs, that we're going after very aggressively. As I said on my previous call, 1 of them is already under contract, and at this point we're working the downstream accounts so they'll pick up coverage for ZUNVEYL; we believe we're in the very last stages of finalizing a second contract, with another one of those large PBMs. We anticipate wrapping that up before this quarter ends. Looking ahead to Q1 and Q2, we're already zeroing in on those downstream accounts, holding regional payer calls to make certain they pull the contract through and cover ZUNVEYL. Across all 4 of these plans, the split is even. In other words, you can figure each plan accounts for roughly 25% of long-term care lives. We feel very good about where things stand at the moment, with launch so near. We've secured 1. Now we need to pull it through. Hopefully we'll land another before this quarter closes, and then, clearly, we'll pull that through during Q1 and Q2 of next year. Naturally, we remain in close negotiations with the remaining 2. Understood. Thank you very much for the update. That's quite useful. Yes, that was quite useful. You referred to 15% coverage, one five, with no restriction at present? Correct. So based on what we can see, when you consider the plan we signed last quarter, the downstream plans need six to nine months to adopt the contract. What we do know is that roughly 15% of them have adopted, and they're processing claims for ZUNVEYL with no restriction whatsoever; we can't see the status of the remaining plans yet, and we'll begin seeing more of that across the coming couple of quarters. Understood. Thank you very much. To dig a bit deeper into the details, you brought up the count of unique prescribers for ZUNVEYL, and the shift there, and how many of them — the split between repeat and new prescribers. Certainly. Since launch through today, in Q3 specifically, we had 576 prescribers, and among them, 62% wrote multiple orders. Looking from launch through today, when we examine the homes, since the orders originate from the homes, we find 605 homes have ordered ZUNVEYL. 70% of those homes have placed repeat orders, while an additional 15% are new homes prescribing in September, the quarter's final month. We're witnessing plenty of repeat ordering; we're also hearing plenty about repeat ordering. Essentially, the broad feedback we get from physicians is that once they give it a try, they begin slowly, they test the product, and you need to allow a little time; this is a frail elderly population. As soon as they observe outcomes in a patient or 2, their writing volume increases considerably. You have to get past that first prescription phase, the trial of the product, and after that they will prescribe for a few additional patients, and at that point it begins to build on itself. A good amount of repeat orders are coming in. Ram, I believe a key point — this is what I brought up while walking through my section — is that beyond the fact that they are writing a good deal, the writing is happening month over month. Double-digit growth is what we are seeing, and patients are reaching the 10 mg dose. That matters enormously, since across the past 30 years, with these products, the majority of such patients sit at a subtherapeutic dose. They can titrate the patient. Half of our prescriptions are at the 10 mg dose; nobody has witnessed that in this market, and the reason is that the drug performs the way it was designed to. Excellent. I appreciate all the detail. Could I get one additional question — when do you anticipate beginning? It concerns galantamine, royalty revenue, out of China.
Right. It likely won't happen before 2027 where mainland China is concerned, though a handful of smaller nations in Asia ought to secure their approvals during 2026. Once those approvals come through, we'd begin selling right away, meaning the company would record revenue in the same quarter it launches within each of those markets. Understood. I really appreciate you fitting in my questions.
Excellent. To start, I'd like to congratulate you on the impressive increase in sales. And on that note, perhaps you could share which main marketing points seem to be connecting with prescribers, and what objection comes up most often?
That's a wonderful question. What I'd say is that it varies by the type of stakeholder — we're calling on a number of different customers within the home. Some central messages truly connect with that particular customer. Broadly speaking, we're picking up quite a bit of favorable feedback regarding how ZUNVEYL affects behaviors. As we've mentioned in previous quarters, we changed our messaging; we learned early that prescribers were observing a notable effect on patients who exhibit behaviors and who also clearly have mild to moderate Alzheimer's. We began emphasizing that; we have data on ZUNVEYL that is consistent with the label, demonstrating a meaningful behavioral advantage; that's likely among the most powerful messages we're putting out there. I believe a great many providers are quite drawn to the absence of any effect on sleep. That's an important key message for us. We anticipated that before launch, since if you consider donepezil, which naturally is the market leader, it has a strong link to insomnia, sleep disorders, and nightmares. That particular point is connecting strongly, because a large share of our business is arriving via switches, and much of that relates to the lack of insomnia. I'd say those are our two leading messages. On the whole, I think the set of benefits that ZUNVEYL offers is genuinely valuable for all of these customers in this particular patient population.
Right; regarding resistance?
Yeah. No. When it comes to pushback, I wouldn't claim we're receiving any from ZUNVEYL, messaging as such. Clearly, I believe one of our primary sources of pushback involves navigating payer hurdles, assisting the prescriber and the homes with processing prior authorizations whenever those are needed. Regarding messaging and the drug-working experience for ZUNVEYL, that's performing much better than we anticipated. I think our largest pushback concerns how we can assist in supporting them through the prior authorization process so the drug can secure approval? That's the reason we've placed such a strong emphasis on expanding our reimbursement support team; we've learned an enormous amount in a very brief period about how to make sure we can deliver that support, and that's truly where our focus lies. We've grown that team. We're coordinating with providers. We're offering support so they understand how to properly complete prior authorizations so the drug gets approved. What I can tell you about that is if the PA is filled out properly, a very, very high percentage of approvals. That's genuinely where our team is concentrated at the moment.
Understood. For my final question, perhaps regarding that WAC adjustment you mentioned — could you lay out precisely what that involves? It's possible I overlooked the specifics, and also what effect it has on gross-to-net, plus roughly what happens to your revenue per patient.
Of course. A price increase was implemented by us, since what we observed is this: across the long-term care sector, when you examine CNS products, and payers confirm that this product carried the value that allowed us to raise the price; no resistance at all has come from that price increase. When it comes to gross-to-net, our percentages remain very high. As we've told you, there is a single contract in place. Only around 15% has been seen, an offer lacking any restrictions. At this stage, GTN remains extremely, extremely high. Michael, I'm not sure whether you'd like to weigh in on that.
Yes, I'll include that. I’m figuring a short-term bump of nine points to 9%, regarding how that pricing lands and where it settles. Our expectation remains that ZUNVEYL will carry a net price between $500 and $550.
Sure. In terms of percentages, gross-to-net should come out somewhere around the middle to higher end of a 20% discount, if we're looking strictly at percentage terms. All right. I really appreciate your time on my questions.
Hello, and thanks for fielding my questions. I wanted to circle back to something. Earlier you noted that roughly half of prescriptions are going to the 10 mg strength. Might you elaborate a bit on how demand differs across the various strengths, and how that shifts as physicians grow more at ease with the product?
Absolutely. At launch, a large portion were immediately on the 25, since patients must complete that titration window of four to eight weeks, particularly given how frail this group is. Among most prescribers, the guiding principle in nursing homes tends to be begin at a low dose and increase it gradually. Our expectation was actually that the mix would move toward 50 mg to a greater degree as time went on. We anticipated that this transition would show up more during Q4 and Q1 of the following year; given this patient population, we assumed it would require considerably more time before prescribers felt at ease raising patients to 10 mg. For decades, with the treatment options that existed, they had been unable to increase the dose. It was encouraging to observe the actual pattern, because with such low AEs reported, as prescribers have gained experience with the product, they are clearly becoming more at ease with rapid titration, which explains the 50/50 split in Q3, occurring far sooner than we had anticipated. I'm not certain whether that addresses your question regarding our expectations and prescriber confidence, but I believe what we're observing is that physicians try it, naturally, at the initial dose. And after a handful of their patients reach the 10s, they clearly grow more confident — you know what I mean — in titrating their other patients, whom they start somewhat more rapidly. Rather than possibly waiting eight weeks, they wait four weeks. We are clearly witnessing quicker acceleration up to the 10s, which speaks directly to how tolerable this product is.
Understood. That is exactly what I was looking for. Thank you for that, Laura.
Certainly.
I'll ask one additional question. What's the shape of the sales cycle at this point? You've now had a presence in the market for 2 quarters. Has that cycle been getting shorter? What about the ratio between prescriber interactions and orders — is the count of interactions needed to produce orders coming down? And do you have any stories of prescribers who already knew about ZUNVEYL ahead of that first call? Anything along those lines?
Certainly. At this moment, what we observe is that with a launch, particularly in long-term care, every provider is going to begin gradually. Even a provider who may have participated in the trials will begin with 2 patients, observe the results, and then they will clearly titrate, observe the results, and then they will begin broadening the patients who might be a possible candidate for ZUNVEYL; that is what we have observed. What we are now observing is that physicians who are beginning to prescribe much more, they speed up faster. It is essentially a gradual beginning for everyone, simply because of the fragile patient population and the reality that they have been disappointed for decades in this category of drugs. After they begin, you start to observe them grow their patient base more quickly. Our emphasis at present from a sales standpoint, since our homes are, as I mentioned somewhat during the call, many of them are ordering repeatedly. Seventy percent of our homes have orders coming in again. That is an extremely high target or an extremely high metric, for a launch brand in only 2 quarters. We definitely are observing that for those providers who have given it a try, they have allowed time for it, there is a faster sales call, clearly, for them to try it once more and use it with more patients. Usually, that HCP naive patient, who has not given it a try, you are looking at 2 months before you can get them to give it a try. Clearly, they are going to wait. They are going to titrate. It takes a bit before they feel at ease.
Understood. Thank you for the call.
Sure.
That wraps up the Q&A portion, folks, and it also brings an end to today's teleconference. We appreciate everyone joining in. You may now hang up, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Alpha Cognition Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Alpha Cognition Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.